BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35038557)

  • 1. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Guzmán-Puche J; Pérez-Nadales E; Pérez-Vázquez M; Causse M; Gracia-Ahufinger I; Mendez-Natera A; Allalou-Ruiz Y; Elías C; Oteo-Iglesias J; Torre-Cisneros J; Martínez-Martínez L
    Int J Antimicrob Agents; 2022 Feb; 59(2):106524. PubMed ID: 35038557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KPC-2 allelic variants in
    Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
    Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
    Shen S; Tang C; Yang W; Ding L; Han R; Shi Q; Guo Y; Yin D; Hu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2356146. PubMed ID: 38743401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms Driving the
    Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
    mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
    van Asten SAV; Boattini M; Kraakman MEM; Bianco G; Iannaccone M; Costa C; Cavallo R; Bernards AT
    J Infect Chemother; 2021 May; 27(5):778-780. PubMed ID: 33558042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.
    Piazza A; Mattioni Marchetti V; Bielli A; Biffignandi GB; Piscopiello F; Giudici R; Tartaglione L; Merli M; Vismara C; Migliavacca R
    J Microbiol Immunol Infect; 2024 Jun; 57(3):457-469. PubMed ID: 38584042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of ceftazidime-avibactam resistance in bla
    Zhou J; Yan G; Tang C; Liu J; Fu P; Ding L; Yang W; Guo Y; Wang C; Lu G; Hu F
    Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant
    Wu Y; Yang X; Liu C; Zhang Y; Cheung YC; Wai Chi Chan E; Chen S; Zhang R
    Microbiol Spectr; 2022 Apr; 10(2):e0265521. PubMed ID: 35416703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P; Bovo F; Bussini L; Lazzarotto T; Amadesi S; Bartoletti M; Viale P; Ambretti S
    J Antimicrob Chemother; 2022 May; 77(6):1570-1577. PubMed ID: 35373297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    Zheng M; Li FH; Liu J; Li WJ; Yin RX; Cai DT; Andrey DO; Zheng SL; Gales AC; Zhang WJ; Sun J; Liao XP; Yu Y
    J Antimicrob Chemother; 2024 May; 79(5):1069-1080. PubMed ID: 38526879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.
    Carattoli A; Arcari G; Bibbolino G; Sacco F; Tomolillo D; Di Lella FM; Trancassini M; Faino L; Venditti M; Antonelli G; Raponi G
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0057421. PubMed ID: 34339281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
    J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-Avibactam Resistance Associated with Increased
    Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.